Fig. 1/10



BEST AVAILABLE COPY

Fig. 2/10

A



B



C

	Trainings set Errors in crossvalidation	Test set Test errors
MSI	6.48% (n=25, range 0-4)	6.0% (n=9, range 0-3)
MSS	1.67% (n=30, range 0-3)	1.62% (n=37, range 0-4)
All	3.85% (n=55, range 0-5)	2.48% (n=46, range 0-4)

BEST AVAILABLE COPY

Fig. 3/10



BEST AVAILABLE COPY

Fig. 4/10



BEST AVAILABLE COPY

Fig. 5/10


A Patients with stage II Colon Cancer (no adjuvant Chemotherapy)
Overall Survival (%)
Microsatellite Instabile Tumors
Microsatellite Stabile Tumors
P=0.0014
Month after Surgery
No. at risk
Microsatellite instable 17 17 17 17 17 17 17
Microsatellite stable 19 18 15 13 13 13 9
B Patients with stage III Colon Cancer (adjuvant Chemotherapy)
Overall Survival (%)
Microsatellite Stabile Tumors
Microsatellite Instabile Tumors
P=0.55
Month after Surgery
No. at risk
Microsatellite instable 16 13 9 7 7 7 7
Microsatellite stable 49 45 36 30 28 27 19

Fig. 6/10



BEST AVAILABLE COPY

Fig. 7/10



BEST AVAILABLE COPY

Fig. 8/10



BEST AVAILABLE COPY

Fig. 9/10

A


1
5
9
13
17
21
25
29
33
37
-8
-4
0
4
8
*
Sporadic microsatellite instable tumors
Hereditary microsatellite instable tumors

B


Signal intensity
MLH1
Signal intensity
PIWIL1
*
Sporadic microsatellite instable tumors
Hereditary microsatellite instable tumors

Fig. 10/10



BEST AVAILABLE COPY